ScholarLens Back to search
2014•Inter J Epidemiol Infect DisRequires access

Recent progress in NS3/4A protease inhibitors against hepatitis C virus

Mingjia Dai, Xuebing Yan

Open publisher page 0 citations

Abstract

Pegylated interferon (PEG-IFN) and ribavirin(RBV) are regarded as the standardized treatment for chronic hepatitis C (CHC) which is caused by HCV infection.In recent years,with the development of protease inhibitors (PIs),triple therapy has shown good antiviral ability,and brings hope for patients who cannot tolerate or accommodate to IFN therapy.Based on the importance of NS3/4A protease in virus maturation and replication processes,and the wide prospect of protease inhibitors,the structural characteristics of HCV NS3/4A protease and its inhibitors are reviewed in this article. Key words: Hepacivirus;  Protease inhibitors;  Direct acting antiviral agents;  Resistance

About this research paper

What this paper is about

Pegylated interferon (PEG-IFN) and ribavirin(RBV) are regarded as the standardized treatment for chronic hepatitis C (CHC) which is caused by HCV infection.In recent years,with the development of protease inhibitors (PIs),triple therapy has shown good antiviral ability,and brings hope for patients who cannot tolerate or accommodate to IFN therapy.Based on the importance of NS3/4A protease in virus maturation and replication processes,and the wide prospect of protease inhibitors,the structural characteristics of HCV NS3/4A protease and its inhibitors are reviewed in this article. Key words: Hepacivirus;  Protease inhibitors;  Direct acting antiviral agents;  Resistance

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Pegylated interferon (PEG-IFN) and ribavirin(RBV) are regarded as the standardized treatment for chronic hepatitis C (CHC) which is caused by HCV infection.In recent years,with the development of protease inhibitors (PIs),triple therapy has shown good antiviral ability,and brings hope for patients who cannot tolerate or accommodate to IFN therapy.Based on the importance of NS3/4A protease in virus maturation and replication processes,and the wide prospect of protease inhibitors,the structural characteristics of HCV NS3/4A protease and its inhibitors are reviewed in this article. Key words: Hepacivirus;  Protease inhibitors;  Direct acting antiviral agents;  Resistance

Key concepts: Protease, Ribavirin, NS3, Hepatitis C virus, Virology, Pegylated interferon, Protease inhibitor (pharmacology), Hepatitis C

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Recent progress in NS3/4A protease inhibitors against hepatitis C virus — Research Paper | ScholarLens